Agenix (ASX:AGX) subsidiary AGEN BioMedical has licensed its D-Dimer antibody and associated intellectual property to US point-of-care diagnostics company Biosite. [ + ]

As the Australian Genome Research Facility continues its drive to get AUD$6 million funding for the sequencing of the wallaby genome, the benefits of participating in a 'big science' project like this are becoming apparent. [ + ]

Melbourne University epilepsy investigator Dr Steve Petrou has received a prestigious National Institutes of Health grant to study what happens in the brain of a transgenic mouse that exhibits human-like epileptic seizures. [ + ]

Peptech (ASX:PTD) has entered into a joint venture with University of Sydney spin-off Biosceptre International to develop a range of diagnostic and therapeutic products based on a specific cancer marker expressed in a broad range of human cancers including skin, prostate, breast, bowel and uterine cancers. [ + ]

With a hint of alchemy, University of Melbourne scientists have shot carbon atoms into glass and by adding a bit of heat, turned them into nanometre-sized diamonds with properties that could create help create a quantum computer.

Global warming is making nights warmer around the globe and from pole to pole, and will have major effects on plant photosynthesis and productivity, according to Columbia University plant physiologist Dr Kevin Griffin. [ + ]

BresaGen (ASX:BGN) is likely to become a holding company with stakes in several businesses, including a new stem cell company formed by the merger of BresaGen's cell therapy division with San Diego stem cell company CyThera, CEO John Smeaton told the company's AGM yesterday. [ + ]

Norwood Abbey (ASX:NAL) executive chairman Peter Hansen told shareholders at the company's AGM yesterday that the first revenues from the company's laser assisted drug delivery device would flow into the company in late December or early January. [ + ]

AgGenomics, a joint venture company owned by Melbourne-based Genetic Technologies (ASX:GTG) and the Victorian government, has been selected as the exclusive Australian provider of DNA profiling services for the selection of A2 dairy cattle for New Zealand company A2 Corporation. [ + ]

Monash University and big German pharmaceutical company Schering AG have announced a collaborative research and licensing agreement to develop new therapies for prostate disease, male infertility, and new male contraceptives. [ + ]

The Peter MacCallum Cancer Centre has spun out its cellular therapies services into a small company called Cell Therapies, in order to make the most of its TGA-licensed Centre for Blood Cell Therapies. [ + ]

Members of South Australia's BioAngels have made their first investment into the South Australian bioscience sector, selecting Australian Orthopaedic Innovations from more than 20 applications. [ + ]

Queensland's reputation as a hub for scientific innovation will be further enhanced next year when work begins on the $60 million Australian Institute of Bioengineering and Nanotechnology (AIBN) complex at The University of Queensland.

Diagnostics company Rockeby Biomed is readying itself to float on the ASX in a back door listing through Carbine Corporation. [ + ]

Perth-based nanomaterials specialist pSivida (ASX:PSD) has acquired the rights to use porous silicon mirror technology from German research agency Forschungszentrum Julich. [ + ]